US FDA to rule on Eliquis in 2nd go-round by 17 March
This article was originally published in Scrip
Executive Summary
US drug makers Bristol-Myers Squibb and Pfizer are hoping the luck of the Irish are with them on their on the second go-around with experimental anticoagulant Eliquis (apixaban) at the US FDA, which has set 17 March as the date by which it will rule on whether to approve the medicine as a treatment to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).